New study tests if adding a second drug boosts UC treatment

NCT ID NCT07442045

Recruiting now Disease control Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study looks at whether using two drugs together (upadacitinib and vedolizumab) works better than just one drug (upadacitinib alone) for people with moderate-to-severe ulcerative colitis, a chronic bowel disease. Researchers will review medical records from 150 adults across six hospitals in China to see which approach leads to more symptom relief and fewer side effects during the first 8 weeks of treatment. The goal is to provide real-world evidence to help doctors choose the best treatment plan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

Foshan Fosun Chancheng Hospital, Foshan
RECRUITING

Foshan, Guangdong, 528000, China
The First People's Hospital of Foshan
RECRUITING

Foshan, Guangdong, 510260, China
The Second Affiliated Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, 510260, China
The Sixth Affiliated Hospital, South China University of Technology City: Foshan
RECRUITING

Foshan, Guangdong, 528200, China
the Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Bao'an District)
RECRUITING

Shenzhen, Guangdong, 518000, China
the Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 501655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.